Introduction
Cutaneous melanoma is the most aggressive form of skin cancer, with a high mortality rate if not treated in a timely manner [1] . Although melanomas are far less common than other cutaneous carcinomas, such as basal cell carcinomas (BCC) or squamous cell carcinomas (SCC), melanomas account for the majority of deaths from skin cancer [2] [3] [4] . It is estimated that in 2015 there will be 9,940 deaths from melanoma, and 74,000 new cases of this malignancy [5] . Therefore, careful attention to established risk factors, especially in individuals prone to melanoma development, is important for detecting malignant lesions in their early stages [6, 7] . When detected early, melanoma is quite curable -the five-year survival rate of Stage 1A melanoma is 91-99% [8] . However, with increasing tumor stage, the survival rate drastically decreases to 65-73% for stage IIIA tumors and 16-22% for stage IV tumors [8] . Thus, early detection and treatment of these malignant neoplasms is crucial to improving the probability of survival.
Procedures for detecting, staging, and treating melanomas have been well established [9, 10] . Nevi that satisfy the wellknown mnemonic ABCDE for basic melanoma identification [11] (asymmetry, border irregularity, color variation, diameter > 6 mm, and tumor evolution) indicate suspicious lesions. This mnemonic may assist patients in identifying potentially harmful lesions and prompt them to present to a dermatologist to have these lesions evaluated by a trained eye. Melanoma tumors are staged according to depth of invasion, according to the Breslow depth, which has been shown to be an accurate indicator of prognosis and helpful guide in subsequent management [9, [10] [11] [12] . According to guidelines from the National Comprehensive Cancer Network (NCCN), in situ tumors should be excised with surgical margins of 0.5-1.0 cm, ≤1.0 mm-thick lesions with 1.0 cm margins, and 1.01-2.0 mm-thick tumors with 1.0-2.0 cm margins ( Objective: To evaluate patterns in treatment timeframes recommended and employed by American GD and PD programs for stage 0 and 1A melanomas.
Methods:
Anonymous online survey (SurveyMonkeyTM) distributed to all GD and PD program directors in the US.
Results: 180 programs were surveyed. 59.4% (n=38) of the 64 respondents were GD, while 35.9% (n=23) were PD. For stage 0 melanomas, four weeks after diagnosis was the most common recommended treatment timeframe (43.8%, n=28), followed by two weeks (31.3%, n=20). For stage 1A tumors, two weeks was most commonly recommended (43.8%, n=28), followed by four weeks (28.1%, n=18).
Conclusions:
Most respondents recommended treating stage 0 and 1A melanomas within two or four weeks of diagnosis. The most common recommendation for stage 0 tumors was within four weeks, while two weeks was preferred for stage 1A tumors. structures [9, [10] [11] [12] . Ideally, these tumors should be excised as soon as the diagnosis of melanoma has been rendered, but due to variations in clinic availability and scheduling, immediate treatment is not always possible [14, 15] . However, no recent studies have established a maximum recommended time period between diagnosis and excision of stage 0 (melanoma in situ) and 1A tumors, and there are currently no official guidelines set by the National Comprehensive Cancer Network (NCCN), American Academy of Dermatology (AAD), or other comparable organizations that specify a timeframe for treatment. Therefore, it may be helpful to explore the typical timeframes currently recommended between diagnosis and treatment of stage 0 and 1A melanomas by general dermatology (GD) and procedural dermatology (PD) teaching programs in the United States (U.S.). Thus, we conducted a nation-wide survey of GD and PD teaching programs in order to assess the most common excision timeframes used for treatment of stage 0 and 1A tumors in the U.S.
Methods
An anonymous online survey was created with SurveyMonkey 
Results
Of the 180 GD and PD program directors surveyed, 35.6% (n=64) responded. Of the 64 respondents, 62.3% (n=38) were from GD residencies, while 37.7% (n=23) were from PD fellowship programs.
For stage 0 melanomas, four weeks after diagnosis was the most common recommended timeframe for treatment (43.8% of all programs, n=28), followed by two weeks (31.3%, n=20), one week (7.8%, n=5), three weeks (4.8%, n=4), and 1-3 days (1.6%, n=1). In addition, when analyzed separately, both GD and PD programs indicated that a four-week period after establishment of diagnosis was the most commonly suggested timeframe for excision of these tumors (Table 2) .
On the other hand, for stage 1A tumors, two weeks was the most common recommended time period (43.8% of all programs, n=28), followed by four weeks (28.1%, n=18), one week (10.9%, n=7), three weeks (4.7%, n=3), and 1-3 days (1.6%, n=1). However, when GD and PD responses were analyzed separately, we found that the most common treatment timeframe recommended by GD program directors was two weeks (55.3%, n=21), while the time period used by most PD programs was four weeks (34.8%, n=8). However, this did not reach statistical significance.
Most respondents reported being able to schedule greater than 90% of patients within their recommended timeframes (67.7%, n=42 for stage 0 tumors; 64.5%, n=40 for stage 1A tumors) ( Table 3) .
Discussion
Although melanoma only accounts for 5% of all skin cancers diagnosed in the U.S. [8] , it is responsible for the majority of deaths from skin cancer [5, 11, [16] [17] [18] . One of the most crucial factors in improving the probability of survival is the detection of malignancy while the tumor is still superficial (i.e. in stage 0 or 1A) and has not yet invaded into underlying structures. With increasing tumor invasion, survival rates drop steeply [9] . Thus, it is imperative to detect and treat malignant lesions as early as possible.
While guidelines for melanoma staging and excision margins have been well established [10, 12] , there have been no recent studies on recommended time periods between diagnosis of melanoma and actual excision of the tumor. Although immediate treatment is the best method for preventing tumor progression and disease recurrence, it is not always possible to excise the lesion upon diagnosis, and typically, there is a lag between detection of the tumor and surgical excision. Many studies have focused on factors that contribute to the delay of melanoma diagnosis-abilities of physicians to recognize malignant tumors, patients' lack of awareness of suspicious skin lesions, and decreased motivation to present to clinic [6, [19] [20] [21] . Additionally, the method of diagnosis is crucial -previous studies have indicated that excisional biopsy appears to be the most reliable way of detecting malignant lesions, in contrast to other techniques such as incisional, shave, or punch biopsies [22] [23] [24] . Selection of an inappropriate diagnostic modality due to lack of suspicion of a malignant tumor may also lead to a delay in melanoma diagnosis. Lott et al. found that about one in five Medicare beneficiaries experienced a delay in surgical treatment of melanoma of longer than 1.5 months, which was largely dependent on whether the tumor was biopsied by a dermatologist or non-dermatologist [25] . As these findings suggest that there may be coordination issues that can potentially shorten the delay in surgical treatment, it is important to evaluate the excision timelines followed by dermatology clinics. Furthermore, since no recent studies have reported the typical timeframe of tumor excision once a diagnosis has been made, and there are no established guidelines for specific excision timelines, it may be useful to be aware of the common timeframes employed by dermatologists in treating stage 0 and 1A melanoma lesions. To the best of our knowledge, there have also been no similar studies for basal cell and squamous cell carcinomas (BCCs, SCCs).
For stage 0 tumors, it appears that most GD and PD programs recommend excising tumors within a four-week period. In contrast, for stage IA tumors, while most PD programs still employed a four-week maximal time period for excision after establishment of a melanoma diagnosis, most GD training programs recommended excising these tumors sooner, within a two-week time period. However, this trend was not statistically significant. As our sample sizes are small for both groups, further studies involving larger survey pools are needed to further elucidate these results.
There are limitations to this study. First, only directors of GD and PD training programs were surveyed. Although program directors are generally cognizant of the practices of their colleagues and trainees and likely reported the treatment strategies most commonly utilized by their programs, it is possible that their responses do not accurately reflect the excision timeframes employed by the individual dermatologists and trainees within the program. In addition, only academic centers were surveyed, and the sample sizes for both GD and PD groups were small. Finally, information regarding melanoma recurrence and survival rates was not garnered in this survey. Future ISSN: 2373 ISSN: -1044 large multi-center studies that involve surveys of all trainees and faculty members in GD and PD programs, as well as information regarding outcomes and recurrences are warranted in order to further assess our preliminary findings.
Overall, this study shows the patterns of stage 0 and IA melanoma management in academic centers in the U.S. Since there are no recent studies or official guidelines outlining specific timeframes for excision of these lesions, it may be helpful to discover the most common treatment timelines that are currently employed by dermatologists across the nation. The preliminary findings from this study are important for establishing the foundation for future investigations concerning the management of early stage melanomas.
